ReviewInfectious diseases & immunity2025
Unveiling emerging threats: Langya and Mojiang-A dance with unfamiliar foes.
Review in Infectious diseases & immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A risk-gate mechanistic-ecological framework for assessing emergence potential of henipa-related viruses.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Langya henipavirus (LayV) and Mojiang henipavirus (MojV) are emerging zoonotic pathogens that were first identified in China in 2018 and 2012 respectively, and are classified within the Henipavirus genus. This article presents an in-depth review of LayV and MojV, focusing on their structural properties, viral entrance, and consequences for human health. The pathogenic potential of these viruses is investigated in depth as well as the current diagnostic methods for identifying LayV and MojV. Furthermore, treatment methods for controlling LayV and MojV infections are assessed, with a particular emphasis on the critical need for tailored antiviral research. This review serves as a critical resource for researchers and healthcare professionals, offering an up-to-date synthesis of knowledge on LayV and MojV while underscoring their significance in public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.